Skip to main content

Table 2 Reason for and characteristics of switching

From: Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

  Total N(748) 4 mg N(226) 8 mg N(509) <65 yr. N(418) ≥65 yr. N(330)
Driven treatment change, %      
 Patient request 24.8 29.8 21.7 24.7 24.9
 Investigator decision 75.2 70.2 78.3§ 75.3 75.1
Principal reason for switching, %      
 Lack of effectiveness 66.8 58.0 70.9§ 67.0 66.7
 Side-effects 18.4 23.5 16.1 17.0 20.3
 Bad compliance 6.1 8 5.3 7.2 4.8
 Others 8.5 10.5 7.7 8.9 8.2
Treatment length, mean (SD), d. 66.2(36.2) 60.1(34.8) 68.8(36.7)§ 63.8(36.1) 69.2(36.2)§
Treatment compliance £, % 31.0 24.9 33.5§ 31.6 30.3
  1. ‡at the time of study visit; £:% of compliers (4 Morinsky-Green questions answered correctly); *:p between groups < 0.001; §:p between groups < 0.05.